Table II.
Concurrent medication use and lamotrigine dosing in conversion and control period (n = 1092)
| Characteristic | Conversion period
|
Control period
|
p-Value | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Concurrent drug therapy | |||||
| Anxiolytics | 246 | 39.9 | 254 | 41.2 | 0.3524 |
| Antidepressants | 319 | 51.8 | 316 | 51.3 | 0.6547 |
| Antiepileptic drugs | 207 | 33.6 | 197 | 32.0 | 0.1573 |
| Antipsychotics | 245 | 39.8 | 252 | 40.9 | 0.2858 |
| Mood stabilizers | 34 | 5.5 | 25 | 4.1 | 0.0027 |
| Triptans | 14 | 2.3 | 13 | 2.1 | 0.7055 |
| >5 concurrent prescriptions | 309 | 50.2 | 317 | 51.5 | 0.4927 |
| Mean prescription fill count [SD] | 7.44 [7.2] | 7.74 [7.5] | 0.9635 | ||
| Mean lamotrigine daily dose [SD] | |||||
| Baseline | 282.7 [199.9] | 250.5 [162.6] | |||
| Observation | 281.3 [170.1] | 259.2 [164.4] | |||
| Change in dose | −1.4 | 114.9 | 8.7 | 40.2 | |
| Difference in changes | 10.0 | 121.7 | <0.0001 | ||